Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate

The continuing high global incidence of COVID-19 and the undervaccinated status of billions of persons strongly motivate the development of a new generation of efficacious vaccines. We have developed an adjuvanted vaccine candidate, PHH-1V, based on a protein comprising the receptor binding domain (...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine Jg. 41; H. 35; S. 5072 - 5078
Hauptverfasser: Moros, Alexandra, Prenafeta, Antoni, Barreiro, Antonio, Perozo, Eva, Fernández, Alex, Cañete, Manuel, González, Luis, Garriga, Carme, Pradenas, Edwards, Marfil, Silvia, Blanco, Julià, Cebollada Rica, Paula, Sisteré-Oró, Marta, Meyerhans, Andreas, Prat Cabañas, Teresa, March, Ricard, Ferrer, Laura
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Netherlands Elsevier Ltd 07.08.2023
Elsevier Limited
Schlagworte:
Allergy and Immunology
Amino acids
Animal models
Antibodies
COVID-19
COVID-19 infection
COVID-19 vaccines
Disease transmission
domain
Hogs
Humoral immune response
humoral immunity
IFNγ
Immune response
Immune response (humoral)
Immune system
Immunization
Immunogenicity
Lymphocytes T
Males
mice
Pandemics
Proteins
RBD
Recombinant vaccine
Safety
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Swine
T-lymphocytes
Temperature
Vaccines
Within-subjects design
γ-Interferon
COVID-19
IFNγ
Humoral immune response
SARS-CoV-2
RBD
Recombinant vaccine
ISSN:0264-410X, 1873-2518, 1873-2518
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The continuing high global incidence of COVID-19 and the undervaccinated status of billions of persons strongly motivate the development of a new generation of efficacious vaccines. We have developed an adjuvanted vaccine candidate, PHH-1V, based on a protein comprising the receptor binding domain (RBD) of the Beta variant of SARS-CoV-2 fused in tandem with the equivalent domain of the Alpha variant, with its immunogenicity, safety and efficacy previously demonstrated in mouse models. In the present study, we immunized pigs with different doses of PHH-1V in a prime-and-boost scheme showing PHH-1V to exhibit an excellent safety profile in pigs and to produce a solid RBD-specific humoral response with neutralising antibodies to 7 distinct SARS-CoV-2 variants of concern, with the induction of a significant IFNγ+ T-cell response. We conclude that PHH-1V is safe and elicits a robust immune response to SARS-CoV-2 in pigs, a large animal preclinical model.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0264-410X
1873-2518
1873-2518
DOI:10.1016/j.vaccine.2023.07.008